Successful treatment of a patient with refractory haemophagocytic syndrome in systemic lupus erythematosus with mycophenolate mofetil. Issue 2 (3rd July 2017)

• Record Type: Journal Article
• Authors: Sugiyama, Yumiko; Minegishi, Kaoru; Hamada, Naoki; Nagai, Hideto; Tatekabe, Yuko; Tsuchida, Naomi; Soejima, Yutaro; Kunishita, Yosuke; Kishimoto, Daiga; Nakano, Hiroto; Kamiyama, Reikou; Tamura, Maasa; Yoshimi, Ryusuke; Asami, Yukiko; Kirino, Yohei; Ueda, Atsuhisa; Nakajima, Hideaki
• Is Part Of: Modern rheumatology case reports. Volume 1:Issue 2(2017)
• Page Start: 79
• Page End: 83
• Publication Date: 2017-07-03
• Subjects: Systemic lupus erythematosus -- haemophagocytic syndrome -- mycophenolate mofetil -- pancytopenia -- refractory haemophagocytic syndrome; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/24725625.2017.1291176
• Languages: English
• ISSNs: 2472-5625

Abstract

Abstract: Haemophagocytic syndrome (HPS) is one of the most severe complications of systemic lupus erythematosus (SLE). Although corticosteroids are usually selected as an initial treatment, some patients are corticosteroid-resistant and require additional immunosuppressants. Here, we report a case of SLE-associated HPS patient who was resistant to prednisolone, calcineurin inhibitors, cyclophosphamide, plasma exchange and infliximab but was successfully treated with mycophenolate mofetil (MMF). MMF could be an alternative treatment for intractable HPS complicated with SLE.